Using rTMS to treat pleasure deficit in adolescent depression
Efficacy and Mechanism of Repetitive Transcranial Magnetic Stimulation on the Symptoms of Pleasure Deficit in Adolescent Depression
This study is testing if a treatment called rTMS can help teenagers with depression feel more pleasure in their lives.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 44 (estimated) |
| Ages | 10 Years to 19 Years |
| Sex | All |
| Sponsor | Xijing Hospital Academic / other |
| Locations | 1 site (Xi'an, Shaanxi) |
| Trial ID | NCT06580249 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the efficacy and safety of repetitive transcranial magnetic stimulation (rTMS) in treating pleasure deficit symptoms in adolescents diagnosed with major depressive disorder (MDD). It will collect data on the pleasure deficit scale before and after treatment, while also exploring the underlying hemodynamic mechanisms associated with rTMS. The study focuses on adolescents aged 10-19 who have not received any antidepressant treatment in the two weeks prior to enrollment. By targeting the dorsolateral prefrontal cortex, rTMS may significantly improve symptoms related to the inability to experience pleasure.
Who should consider this trial
Good fit: Ideal candidates are adolescents aged 10-19 with a diagnosis of major depressive disorder and significant pleasure deficit symptoms.
Not a fit: Patients with psychotic symptoms or other major psychiatric disorders may not benefit from this treatment.
Why it matters
Potential benefit: If successful, this treatment could provide a novel therapeutic option for adolescents suffering from depression characterized by pleasure deficits.
How similar studies have performed: Previous studies have shown that rTMS can effectively improve depressive symptoms, particularly in patients with pleasure deficits, suggesting a promising approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 10-19 years old (both 10 and 19), gender is not limited; 2. Meet the criteria for diagnosing MDD in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5); 3. First episode or relapse, monophasic or bipolar depressive disorder; 4. No history of any form of antidepressant treatment (including medication, physical and psychotherapy) within 2 weeks prior to enrollment; 5. Habitual right-handedness; 6. Deficit of pleasure scale (DARS) \<22 points; 7. Score \>17 on the 17-item version of the Hamilton Depression Scale (HAMD-17); 8. After fully understanding the safety of rTMS, they were willing to actively cooperate with the treatment and signed an informed consent form. Exclusion Criteria: 1. Complicated with psychotic symptoms; 2. Comorbidity with major psychiatric disorders such as schizophrenia, delusional disorder, delirium, neurocognitive disorder, intellectual disability, and other mental disorders caused by other diseases; 3. History of primary neurologic disease or brain injury; 4. History of electroconvulsive therapy; 5. Contraindications to rTMS treatment, including cardiac pacemakers, neurostimulators, artificial metal heart valves, intracranial aneurysm clips, cochlear implants, and other types of metal implants (with the exception of oral supports);(6)History of epilepsy.
Where this trial is running
Xi'an, Shaanxi
- XijingH — Xi'an, Shaanxi, China (Recruiting)
Study contacts
- Study coordinator: Siheng Ma
- Email: matthewsiheng@outlook.com
- Phone: +8613571652479
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.